In Post-Pfizer Growth-To-Value Shift, Russell 2000 Benefits Immensely — ’21 Earnings Estimates Front And Center
November 11, 2020 at 05:28 AM EST
The Russell 2000 rallied huge the last seven sessions, as post-Pfizer news in particular investors have rerated value versus growth. With this, next year’s earnings estimates are front and center.